CalvinBall·Console for/Dabur HPC and Foods
✓ Governed · every figure traceable
Dabur · NSE:DABUR · Q1 FY27 filed 3 Aug 2026
4 BRANDS ABOVE ₹1,000 CR ✦ DECISION LAYER AGENTS TEAMS

Home Care has slowed to mid single digit. Oral Care can carry it, if the herbal claim moves to Meswak.

Dabur Amla · one of four brands above ₹1,000 cr Hair Care strong double digit Q1 FY27 Oral Care near double digit Q1 FY27 Four brands above ₹1,000 cr · 4 Aug 2026
Good morning, Abhishek. Home Care grew mid single digit in Q1 FY27 while Oral Care grew near double digit. One decision is ready to route, with its floor and its owner.
✦
Try
Overnight run · overnight watch
04:02 BST · runs every night
⛁
9
data sources read across the portfolio
≣
38
quarters read, all filed
⛬
4
signals triaged · 2 muted so you don't waste spend
◈
1
decision ready, with owner and floor
◷100%
of figures traced to a filing · 19 of 19
✦ The night shift · agent activity
00:00 → 04:02 BST
↳No dashboard was opened. Every figure is traced to a filing. The decision is yours.

The six categories

growth from the Q1 FY27 filing, share from Q2 FY26
The one decision · caught overnight
Oral Care is carrying the quarter and Home Care is not, an allocation question, not a category-health one.
Oral Care grew near double digit in Q1 FY27 on the Red franchise, Meswak and Dabur Herb’l. Home Care grew mid single digit on Odonil and Sanifresh. Both are filed; the split of effort between them is not.
HPC gap to the stated target
₹3,154 cr
→ ₹3,846 cr FY23, filed · target ₹7,000 cr
How this changes the category review
Same filings. Read as decisions.
Without the layer · today
Today, after the filing lands
○
A category review takes three cycles to reach a decision. The filing is already public.
○
A meeting to align, another to decide. Your agents wait, pointed at last quarter's target.
○
By the time spend moves, the window has half-closed.
→
With the console · now
Monday, before the category review
●
The decision is priced at ₹3,154 cr against ₹3,846 cr filed for FY23, with the filing named on every figure.
●
Three briefs sit ready for your agents and your category heads, one action each.
●
You walk into the CEO's office with the decision, and move on to the next bet.
↳ The shift: from the person who commissions the analysis to the one who walks in with the decision. The layer gives you back the three cycles.
Open the decision and check the figures and watch the guardrail hold.
⤢Core Dabur growth+7.3%▲ consolidated revenue, Q4 FY26Q1 FY27 filed · tap for detail
⤢Oral Care15.8%▲ Red, Meswak and Dabur Herb’lQ1 FY27 filed · tap for detail
⤢Home Caremid single digit▼ slowed from mid twenties in Q4 FY26Q1 FY27 filed · tap for detail
⤢Top categories holding/gaining share51%▼ from 55% · Q2 FY26Q1 FY27 filed · tap for detail
The HPC and Foods portfolio, read as decisions
Each brand leads with the number that moves it · tap any card for detail
Decisions in motion · your playbooks
Built on Dabur's own filings. Category growth is from the Q1 FY27 results of 3 August 2026, share movement from Q2 FY26, and brand tiers from the company release of 4 August 2026. Every figure on this console names the filing it came from. Where a category is not separately disclosed the console says so rather than estimating, and the forecast model has not yet run on Dabur data.
Playbooks·Repeatable motions · human-led & agent-led

The motions the layer runs for you, some by agents, some by people.

A playbook is a decision pattern the console knows how to run end-to-end. It detects the trigger, shapes the decision with a governed trace, and routes execution to whoever does it best, an agent in your suite, or a person on your team. You run it; the layer does the work.
Why·Oral Care · Meswak against Red · Q1 FY27

The growth engine is real. The cover behind it is not keeping up.

Governed trace · four agents · every figure reconciled to source
FetcherRead Q1 FY27, Q4 FY26 and Q2 FY26 results, and the company release of 4 August 20262.0s✓
SQLCompared category growth by region, no free-form generation5.8s✓
KnowledgeApplied Dabur premiumisation logic + category seasonality curves + share-tolerance bands3.1s✓
SupervisorTraced every figure to its filing · 19 of 19 · assumptions stated1.7s✓
The diagnosis · share movement per rupee of cover
where share gained in Q2 FY26
Oral Care grew near double digit, Home Care mid single digit · Q1 FY27 filed
This isn't a category-health problem, Dabur Amla share is holding or rising in every region read. It's an allocation problem: the money is sitting where it has stopped compounding, while demand outruns it elsewhere.
Ranked causes
Each one opens straight into the workflow that fixes it
1
Oral Care demand is outrunning its cover, HPC and Foods & the herbal shift
North India-derived launch (Bio-Infusions launched Q1 FY27, size not disclosed) and double-digit North and West India growth pull demand faster than share of shelf. Opportunity · compounds if funded now
+₹112 crunfunded upside · modelled
↳ Routes to ✍ Content + Supply Agent · Launch Amplify
2
Oral Care growth is outrunning Home Care
Cover has crossed the point where more of it stops paying; share movement ~0.7. The stock sits where demand is already met. Recoverable · move it, do not cut cover
−₹74 crwasted cover · modelled
↳ Routes to ◷ Supply Agent · Catch & Move
3
Share competitiveness slipping where oral care share gap widened
Top categories holding/gaining share fell to 51% from 55% · Q2 FY26 filed. Two established regions crossed the tolerance band. A content + category management answer, not a list-price cut.
−0.6pts share · Q2 FY26
↳ Routes to RP Ravi P. · Lead · Premium Defence
▴ Structural or fixable this cycle · read before the EXCO
Of the Oral Care upside, ~₹40 cr is category growth that accrues anyway, it accrues whether or not you act, and claiming it as a gain would be dishonest. What your the move actually moves is the ₹72 cr that needs share of shelf to convert plus the ₹74 cr of wasted West India cover you move. The honest number is what the decision changes, not the whole pool. Measured, not promised.
The "what to do" is ready. Open the composer to shape the constraints and route it, or take the whole decision to the board.
Brief·Dabur Amla · Q1 FY27 category read · for Abhishek Jugran

The decision, written verdict-first, in your language, sources on every figure.

I have the diagnosis. Generate the board-grade brief. The move, the regions, the measured impact, and the source appendix, then download it or dispatch it.
Dispatch·Decision → your people & your agents

The decision is made here. It routes to the people who own it.

CalvinBall does not set cover or price packs. It decides what to hold, what to move, and what to defend, then routes each piece to the person who owns it.
Your category teams and planners are the muscle. This is the layer above them that turns a portfolio signal into governed, traceable briefs each one can act on. The Supervisor signs off before anything routes. Nothing leaves without your sign-off.
⛬
Portfolio signal
CalvinBall · 04:02
◈
Governed decision
CalvinBall · the brief
✍
Pack Agent
Your suite · creates
◷
Supply Agent
Your suite · executes
◐
Your category head
Your team · decides price
⛨
Supervisor guardrail active. Each payload carries its own source appendix and share floor constraint. The move is bounded to wasted cover · modelled, no market drops below its share floor. A payload that would breach a category guardrail is blocked, not routed.
Routing to your teamsAccenture · platform partners
0 of 4 briefs routed.
Signal·Emerging-issues radar · last 24h

What I caught while no one was watching.

Ranked by value × closing window · the Dabur Amla move fired from signals 1 and 2 · 2 muted so you don't act on noise.
Ask·Portfolio-aware · answers in place

Ask the console anything.

Context: Dabur Amla move · ₹3,154 cr open · 9 live sources
✦ Ask me anything, here's where leaders like you start
✦